MRKMerck Sharp & Dohme LLCSigning up patients
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Bladder Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 400 (planned)
- Started
- Oct 23, 2026
- Main results expected
- Nov 17, 2031
- Fully finished
- Sep 25, 2036
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-Free Survival (EFS)
Measured over: Up to approximately 60 months
Changes Tremor has spotted
Status changed: Not started yet → Signing up patients. Usually normal progress.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- 2026-11-06 15:29 UTC · status_changed · overall_status
old: "NOT_YET_RECRUITING"
new: "RECRUITING"
Trial ID NCT07829783 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC